Novartis delivered solid third quarter
- Details
- Category: Novartis
Net sales were USD 12.1 billion in the third quarter, as volume growth of 5 percentage points was more than offset by the negative impact of generic competition and pricing. Growth Products contributed USD 4.3 billion or 36% of net sales, up 20% (USD) over the prior-year quarter. Operating income was USD 2.3 billion. Core adjustments amounted to USD 1.1 billion (2015: USD 1.3 billion), broadly in line with the prior-year quarter.
Get your startup to the next level
- Details
- Category: Merck Group
The Merck Accelerator is looking for startups with the potential to reshape entire industries and make people's lives richer. The focus is on startups in the fields of healthcare, life science and performance materials - with a digital perspective. Do you have plans to internationalize your business? Are you ready to get your start-up to the next level?
Roche delivers good sales growth in the first nine months of 2016
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that Group sales increased 4% to CHF 37.5 billion. Sales in the Pharmaceuticals Division were up 4% to CHF 29.1 billion, driven by demand for breast cancer medicines Perjeta and Herceptin as well as for Actemra/RoActemra for rheumatoid arthritis.
Pfizer awarded grant to evaluate vaccine to protect newborns against group B Streptococcus infection
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) today announced an award of a grant from the Bill & Melinda Gates Foundation to conduct a Phase 1/2 clinical trial of Pfizer's vaccine candidate against group B Streptococcus(group B strep or GBS) infection, a leading cause of neonatal sepsis, a serious life-threatening blood infection.
FDA approves Roche's cancer immunotherapy TECENTRIQ (atezolizumab) for people with a specific type of metastatic lung cancer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved TECENTRIQ® (atezolizumab) for the treatment of people with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy, and have progressed on an appropriate FDA-approved targeted therapy if their tumour has EGFR or ALK gene abnormalities.
Bristol-Myers Squibb Foundation joins White House Cancer Moonshot
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Foundation joins the White House Cancer Moonshot initiative through its commitment to addressing health disparities in cancer care. In response to the Cancer Moonshot, the Foundation is committing $25 million in new funding to grantee partners to expand the current scope of community-based resources and survivorship support programs to underserved populations in the U.S.
Merck launches Biosimilars Clarified, a new online educational resource about biosimilar medicines for patients and the healthcare community
- Details
- Category: Merck
Merck (NYSE:MRK), known as MSD outside the United States and Canada, has announced the launch of Biosimilars Clarified, a new educational website for patients, caregivers and the healthcare community that is designed to provide clear, concise and straightforward information about biosimilar medicines.
More Pharma News ...
- Daiichi Sankyo announces TaNeDS Europe 2017 collaborative drug discovery programme
- Merck announces recipients of third annual €1 million 'Grant for Oncology Innovation' award
- AstraZeneca enters agreement with Cilag GmbH International to divest rights to Rhinocort Aqua outside the US
- FDA grants Breakthrough Therapy Designation for Roche's Alecensa (alectinib) for first-line treatment of people with ALK-positive NSCLC
- Novartis reports over half of psoriasis patients do not reach the achievable treatment goal of clear skin in largest global survey
- Boehringer Ingelheim and SARAH CANNON Research Institute launch strategic collaboration to develop novel immune-oncology therapies
- Amgen and Arrowhead Pharmaceuticals announce two cardiovascular collaborations